Literature DB >> 12150344

Endocrine aspects of neurosarcoidosis.

G Murialdo1, G Tamagno.   

Abstract

The involvement of the hypothalamus and/or pituitary gland by granulomatous, infiltrative or autoimmune diseases is a rare condition of non-tumoral-non-vascular acquired hypothalamic dysfunction and hypopituitarism. In this paper, we present the case of a 26-year-old woman, who showed an amenorrhea-galactorrhea syndrome with hypogonadotropic hypogonadism due to an isolated hypothalamic-peduncular localization of neurosarcoidosis. Acquired GH deficiency was also demonstrated. This clinical case provided the opportunity for a review of the endocrine aspects linked to brain infiltrative diseases that may affect the hypothalamic-pituitary function, with a focus upon neurosarcoidosis. Sarcoidosis is a pathogen-free granulomatous disease that affects both the central and peripheral nervous system in 5-16% of patients. In most cases, such involvement by sarcoidosis occurs within a multi-systemic disease, but disease localization limited to the nervous system may also be observed. Endocrine manifestations of neurosarcoidosis disclose "chameleon-like" clinical pictures, which are usually expressed by the evidence of hypothalamic dysfunction, diabetes insipidus, adenopituitary failure, amenorrhea-galactorrhea syndrome, in isolated fashion or variedly combined. More rarely, inappropriate anti-diuretic hormone secretion, isolated secondary hypothyroidism, adrenal insufficiency or altered counter-regulation of glucose homeostasis have been reported. Neurosarcoidosis is often hard to diagnose, especially when the neurological localization of the disease is not accompanied by other systemic localizations or by specific signs of the disease, and when the lesion is too deep to obtain bioptic confirmation. The study of cerebrospinal fluid and blood lymphocyte sub-populations, integrated by MRI and nuclear scans (67GalIium uptake and 111Indium-pentetreotide, Octreoscan), may be helpful for a correct diagnosis. Therapy with corticosteroid and immunosuppressive drugs, such as cyclosporine A, and other treatment approaches to neurosarcoidosis are also accounted for.

Entities:  

Mesh:

Year:  2002        PMID: 12150344     DOI: 10.1007/BF03345093

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  109 in total

1.  Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis.

Authors:  J C Dale; J F O'Brien
Journal:  Mayo Clin Proc       Date:  1999-05       Impact factor: 7.616

2.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-1998. A 54-year-old woman with a progressive gait disturbance and painful leg paresthesias.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

3.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-1996. A 51-year-old man with visual problems and an intracranial mass.

Authors: 
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

Review 4.  [Neurosarcoidosis. Comparative analysis of the clinical profile based on 537 cases from the world literature up to 1963 and from 1976-1988].

Authors:  D Mende; R M Suchenwirth
Journal:  Fortschr Neurol Psychiatr       Date:  1990-01       Impact factor: 0.752

5.  Visual evoked potentials in sarcoidosis.

Authors:  L J Streletz; R A Chambers; S H Bae; H L Israel
Journal:  Neurology       Date:  1981-12       Impact factor: 9.910

6.  Central diabetes insipidus as the first manifestation of neurosarcoidosis in a 10-year-old girl.

Authors:  D Konrad; M Gartenmann; E Martin; E J Schoenle
Journal:  Horm Res       Date:  2000

Review 7.  [Neurosarcoidosis. Review of the literature].

Authors:  D Jarnier; C Seriès
Journal:  Neurochirurgie       Date:  1999-09       Impact factor: 1.553

8.  [Peripheral polyneuropathy due to sarcoidosis in a patient with intrathoracic, ocular and skin lesions].

Authors:  M Iwata; M Kondo; M Ando; M Tano; Y Inagaki; Y Shimizu; T Suzuki; K Ito; S Matsumoto; N Shiroyama
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1993-08

9.  Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations.

Authors:  B J Stern; D E Griffin; R A Luke; A Krumholz; C J Johns
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

10.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

View more
  14 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  Neurosarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

Review 3.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

4.  Central diabetes insipidus due to sarcoidosis.

Authors:  Wolter I Q de Waard; Patrick L H van Battum; Remy L M Mostard
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

5.  Diabetes insipidus secondary to sarcoidosis presenting with caseating granuloma.

Authors:  Taimour Alam; Steven Thomas
Journal:  BMJ Case Rep       Date:  2011-03-03

Review 6.  The Clinical Features of Sarcoidosis: A Comprehensive Review.

Authors:  Marc A Judson
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 7.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

8.  Pituitary adenoma with tumoral granulomatous reaction.

Authors:  Bernd W Scheithauer; Ana Isabel Silva; John L D Atkinson; Todd B Nippoldt; Timothy J Kaufmann; Kalman Kovacs; Eva Horvath; Ricardo Lloyd
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

9.  Intracranial Castleman's disease presenting as hypopituitarism.

Authors:  L T Ribeiro; G N Simão; A L M Matos; C G Carlotti; B O Colli; L Neder; A Ribeiro-Silva; M de Castro; E Rego; Antônio Carlos Santos
Journal:  Neuroradiology       Date:  2004-10       Impact factor: 2.804

Review 10.  Idiopathic granulomatous hypophysitis: a systematic review of 82 cases in the literature.

Authors:  Benjamin H M Hunn; William G Martin; Steven Simpson; Catriona A Mclean
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.